Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): An integrated multidisciplinary commentary

Drug Discovery Today

Volumn 18, Issue 21-22, 2013, Pages 1052-1066

  Jarzabek, Monika A ^a   Sweeney, Kieron J ^a,b   Evans, Rhys L ^a   Jacobs, Andreas H ^c   Stupp, Roger ^d   O'Brien, Donncha ^b   Berger, Mitchel S ^e   Prehn, Jochen H M ^a   Byrne, Annette T ^a,f  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ALPHA METHYL TYROSINE I 123; BEVACIZUMAB; BYK 191023; CEDIRANIB; CHOLINE C 11; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; FLUCICLATIDE F 18; FLUORO 3 DEOXYTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROETHYL L TYROSINE F 18; GADOLINIUM PENTETATE; GALACTO ARGININE GLYCINE ASPARTIC ACID F 18; GEFITINIB; METHIONINE C 11; RADIOPHARMACEUTICAL AGENT; SORAFENIB; SUNITINIB; SUPERPARAMAGNETIC IRON OXIDE; TEMSIROLIMUS; THALLIUM 201; UNCLASSIFIED DRUG;

ANTIANGIOGENIC THERAPY; ARTERIAL SPIN LABELLING; BIOLUMINESCENCE; BLOOD OXYGENATION; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DYNAMIC SUSCEPTIBILITY CONTRAST; FLUORESCENCE IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOBLASTOMA; GLUCOSE METABOLISM; HUMAN; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERFUSION WEIGHTED IMAGING; PHOTODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

ANIMALS; BRAIN NEOPLASMS; DISEASE PROGRESSION; GLIOBLASTOMA; HUMANS; MOLECULAR IMAGING; NEOPLASM RECURRENCE, LOCAL;

EID: 84886948024     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.06.004     Document Type: Review

References (104)

1. National Cancer Institute at the National Institutes of Heath. Available at: http://www.cancer.gov/, accessed June 2013.
2. D.N. Louis The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol. 114 2007 97 109
3. R. Stupp Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 10 2009 459 466
4. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
5. M.D. Jenkinson Advanced MRI in the management of adult gliomas Br. J. Neurosurg. 21 2007 550 561
6. P. McConville Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma Clin. Cancer Res. 13 2007 2897 2904
7. J.R. Hesselink, and G.A. Press MR contrast enhancement of intracranial lesions with Gd-DTPA Radiol. Clin. North Am. 26 1988 873 887
8. G.S. Young Advanced MRI of adult brain tumors Neurol. Clin. 25 2007 947 973
9. A. Server Proton magnetic resonance spectroscopy in the distinction of high-grade cerebral gliomas from single metastatic brain tumors Acta Radiol. 51 2010 316 325
10. S. Cha Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging AJNR Am. J. Neuroradiol. 28 2007 1078 1084
11. R.E. Port Noncompartmental kinetic analysis of DCE-MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab Magn. Reson. Med. 64 2010 408 417
12. J.A. Detre Arterial spin-labeled perfusion MRI in basic and clinical neuroscience Curr. Opin. Neurol. 22 2009 348 355
13. E.R. Gerstner Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib Neuro Oncol. 12 2010 466 472
14. M. Kinoshita Diffusion tensor-based tumor infiltration index cannot discriminate vasogenic edema from tumor-infiltrated edema J. Neurooncol. 96 2010 409 415
15. N. Fujiwara Evoked-cerebral blood oxygenation changes in false-negative activations in BOLD contrast functional MRI of patients with brain tumors Neuroimage 21 2004 1464 1471
16. C. la Fougere Molecular imaging of gliomas with PET: opportunities and limitations Neuro Oncol. 13 2011 806 819
17. 11C-choline positron-emission tomography AJNR Am. J. Neuroradiol. 29 2008 1176 1182
18. D.O. Kamson Tryptophan PET in pretreatment delineation of newly-diagnosed gliomas: MRI and histopathologic correlates J. Neurooncol. 112 2013 121 132
19. N. Galldiks Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme Eur. J. Nucl. Med. Mol. Imaging 37 2010 84 92
20. 18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis J. Nucl. Med. 53 2012 207 214
21. A.F. Shields Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat. Med. 4 1998 1334 1336
22. K. Hirata (18)F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas Eur. J. Nucl. Med. Mol. Imaging 39 2012 760 770
23. 18F-labeled alphaVbeta3-integrin and alphaV beta5-integrin imaging agent J. Nucl. Med. 52 2011 424 430
24. B.L. Franc Small-animal SPECT and SPECT/CT: important tools for preclinical investigation J. Nucl. Med. 49 2008 1651 1663
25. T. Semba Thallium-201 SPECT in prognostic assessment of malignant gliomas treated with postoperative radiotherapy Ann. Nucl. Med. 20 2006 287 294
26. Y. Shibata Direct comparison of thallium-201 and technetium-99 m MIBI SPECT of a glioma by receiver operating characteristic analysis J. Clin. Neurosci. 16 2009 264 269
27. D. Kuczer 123I-IMT SPECT for evaluation of the response to radiation therapy in high grade gliomas: a feasibility study Br. J. Radiol. 80 2007 274 278
28. C.W. Lowik Noninvasive real-time in vivo bioluminescent imaging of gene expression and of tumor progression and metastasis Ernst Schering Res. Found. Workshop 49 2005 193 227
29. A. Rehemtulla Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging Neoplasia 2 2000 491 495
30. R. Weissleder, and M.J. Pittet Imaging in the era of molecular oncology Nature 452 2008 580 589
31. A.R. Hsu In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model Mol. Imaging Biol. 8 2006 315 323
32. W. Stummer Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial Lancet Oncol. 7 2006 392 401
33. M. Tripathi Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors Clin. Nucl. Med. 37 2012 158 163
34. O. Mawlawi, and D.W. Townsend Multimodality imaging: an update on PET/CT technology Eur. J. Nucl. Med. Mol. Imaging 36 Suppl. 1 2009 15 29
35. O. Szentirmai Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect Neurosurgery 58 2006 365 372
36. S.C. Jost Measuring brain tumor growth: combined bioluminescence imaging-magnetic resonance imaging strategy Mol. Imaging 8 2009 245 253
37. R. Robertson Optical imaging of Cerenkov light generation from positron-emitting radiotracers Phys. Med. Biol. 54 2009 355 365
38. H.S. Friedman Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J. Clin. Oncol. 27 2009 4733 4740
39. T.N. Kreisl Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J. Clin. Oncol. 27 2009 740 745
40. S.R. Wedge AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Res. 65 2005 4389 4400
41. A. Morabito Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions Oncologist 11 2006 753 764
42. F. Yang Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3 Mol. Cancer Ther. 9 2010 953 962
43. B. Neyns Phase II study of sunitinib malate in patients with recurrent high-grade glioma J. Neurooncol. 103 2011 491 501
44. J.D. Hainsworth Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme Cancer 116 2010 3663 3669
45. M.S. Ahluwalia, and P.Y. Wen Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions Expert Rev. Anticancer Ther. 11 2011 653 656
46. E. Essock-Burns Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma Neuro Oncol. 13 2011 119 131
47. A.G. Sorensen A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res. 69 2009 5296 5300
48. B.M. Ellingson Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity J. Magn. Reson. Imaging 31 2010 538 548
49. T.L. Chenevert Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors J. Natl. Cancer Inst. 92 2000 2029 2036
50. B.M. Ellingson Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab Magn. Reson. Med. 67 2011 237 245
51. M.D. Szeto Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas Cancer Res. 69 2009 4502 4509
52. 18F] fluorothymidine positron emission tomography: a pilot study J. Clin. Oncol. 25 2007 4714 4721
53. 18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma J. Nucl. Med. 52 2011 856 864
54. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat. Rev. Cancer 8 2008 592 603
55. K.V. Lu VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex Cancer Cell 22 2012 21 35
56. F. Ye Therapeutic targeting of EGFR in malignant gliomas Expert Opin. Ther. Targets 14 2010 303 316
57. D.M. Peereboom Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme J. Neurooncol. 98 2010 93 99
58. J.H. Uhm Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074 Int. J. Radiat. Oncol. Biol. Phys. 80 2011 347 353
59. B. Mukherjee EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma Cancer Res. 69 2009 4252 4259
60. C. Panousis Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR Br. J. Cancer 92 2005 1069 1077
61. F.T. Lee Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806 J. Nucl. Med. 51 2010 967 972
62. O.C. Boerman, and W.J. Oyen Immuno-PET of cancer: a revival of antibody imaging J. Nucl. Med. 52 2011 1171 1172
63. C.G. Hadjipanayis EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma Cancer Res. 70 2010 6303 6312
64. E.S. Tykocinski Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma Neuro Oncol. 14 2012 613 623
65. S.A. Wander Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy J. Clin. Invest. 121 2011 1231 1241
66. D. Akhavan mTOR signaling in glioblastoma: lessons learned from bench to bedside Neuro Oncol. 12 2010 882 889
67. Y.J. Zhang Targeting the mTOR kinase domain: the second generation of mTOR inhibitors Drug Discov. Today 16 2011 325 331
68. L.H. Wei Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma Clin. Cancer Res. 14 2008 3416 3426
69. 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma Neuroimage 59 2012 193 201
70. 13C MR spectroscopic imaging Br. J. Radiol. 85 2012 697 708
71. K.L. Pitter Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma PLoS ONE 6 2011 e14545
72. J.F. Curtin Combining cytotoxic and immune-mediated gene therapy to treat brain tumors Curr. Top. Med. Chem. 5 2005 1151 1170
73. P. Dent Searching for a cure: gene therapy for glioblastoma Cancer Biol. Ther. 7 2008 1335 1340
74. A. Jacobs HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis Neoplasia 1 1999 387 401
75. A. Jacobs Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo Cancer Res. 61 2001 2983 2995
76. F. Niola A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model Cancer Biol. Ther. 5 2006 174 179
77. W. Xiong Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain Mol. Ther. 16 2008 343 351
78. J. George Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth J. Cell. Mol. Med. 13 2009 4205 4218
79. A.H. Jacobs Imaging-guided gene therapy of experimental gliomas Cancer Res. 67 2007 1706 1715
80. 18F-FHBG PET in a patient with glioma Nat. Clin. Pract. Oncol. 6 2009 53 58
81. A. Winkeler Switching on the lights for gene therapy PLoS ONE 2 2007 e528
82. F. Colombo Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results Cancer Gene Ther. 12 2005 835 848
83. J. Voges Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma Annal. Neurol. 54 2003 479 487
84. T. Reya Stem cells, cancer, and cancer stem cells Nature 414 2001 105 111
85. T. Borovski Tumor microvasculature supports proliferation and expansion of glioma-propagating cells Int. J. Cancer 125 2009 1222 1230
86. S. Bao Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760
87. C. Tsurumi Non-invasive in vivo imaging of tumor-associated CD133/prominin PLoS ONE 5 2010 e15605
88. C.E. Eyler Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2 Cell 146 2011 53 66
89. X. Fan NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts Stem Cells 28 2010 5 16
90. Y. Waerzeggers Multimodal imaging of neural progenitor cell fate in rodents Mol. Imaging 7 2008 77 91
91. L.Y. Chien In vivo magnetic resonance imaging of cell tropism, trafficking mechanism, and therapeutic impact of human mesenchymal stem cells in a murine glioma model Biomaterials 32 2011 3275 3284
92. T. Doucette Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model Neoplasia 13 2011 716 725
93. T.M. Kauer Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas Nature Neurosci. 15 2012 197 204
94. P.M. LoRusso Phase 0 clinical trials: an answer to drug development stagnation? J. Clin. Oncol. 27 2009 2586 2588
95. D.R. MacDonald Response criteria for phase II studies of supratentorial malignant glioma J. Clin. Oncol. 8 1990 1277 1280
96. P.Y. Wen Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group J. Clin. Oncol. 28 2010 1963 1972
97. S.S. Park MicroPET/CT imaging of an orthotopic model of human glioblastoma multiforme and evaluation of pulsed low-dose irradiation Int. J. Radiat. Oncol. Biol. Phys. 80 2011 885 892
98. S. Nimmagadda Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT J. Nucl. Med. 50 2009 1124 1130
99. G.A. Alexiou The value of 99mTc-tetrofosmin brain SPECT in predicting survival in patients with glioblastoma multiforme J. Nucl. Med. 51 2010 1923 1926
100. 18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme J. Neurooncol. 84 2007 305 314
101. T. Viel Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multimodal small-animal PET and MRI J. Nucl. Med. 53 7 2012 1135 1145
102. H. Jarnum Perfusion MRI of brain tumours: a comparative study of pseudo-continuous arterial spin labelling and dynamic susceptibility contrast imaging Neuroradiology 52 2010 307 317
103. A. Castellano Role of diffusion tensor magnetic resonance tractography in predicting the extent of resection in glioma surgery Neuro Oncol. 14 2012 192 202
104. 18F] Galacto-RGD positron emission tomography Neuro Oncol. 11 2009 861 870